Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148 - PubMed (original) (raw)
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148
S Dan et al. Cell Death Differ. 1998 Aug.
Abstract
The BCR - ABL tyrosine kinase has been implicated as the cause of Philadelphia chromosome (Ph1)-positive leukemias. We report herein that CGP 57148, a selective inhibitor of the ABL tyrosine kinase, caused apoptosis specifically in bcr - abl-positive chronic myelogenous leukemia (CML) cells, K562 and KYO-1. Upon treatment with CGP 57148, CRKL, a specific substrate for BCR - ABL that propagates signals via phosphatidylinositol-3' kinase (PI3K), was dephosphorylated, indicating inhibition of BCR - ABL tyrosine kinase at the cellular level. Likewise, MAPK/ERK, a downstream mediator of Ras, was also dephosphorylated. Caspase activation and cleavage of retinoblastoma protein (pRB) accompanied the development of CGP 57148-induced apoptosis. Inhibition of caspase suppressed apoptosis and the cleavage of pRB, and in turn arrested cells in the G1 phase. These results indicate that CGP 57148 shows apoptogenic and anti-proliferative effects on bcr - abl-positive cells by blocking BCR - ABL-initiated signaling pathways.
Similar articles
- Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Beran M, et al. Clin Cancer Res. 1998 Jul;4(7):1661-72. Clin Cancer Res. 1998. PMID: 9676840 - Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T, Ohki M, Wu N, Kagechika H, Miura O. Kurosu T, et al. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14. Cancer Res. 2009. PMID: 19366808 - Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Wilson MB, et al. Oncogene. 2002 Nov 21;21(53):8075-88. doi: 10.1038/sj.onc.1206008. Oncogene. 2002. PMID: 12444544 - Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J. Kantarjian HM, et al. Clin Cancer Res. 2007 Feb 15;13(4):1089-97. doi: 10.1158/1078-0432.CCR-06-2147. Clin Cancer Res. 2007. PMID: 17317816 Review. - [Molecular targeting therapy for chronic myelogenous leukemia].
Ono R. Ono R. Nihon Naika Gakkai Zasshi. 2003 May 10;92(5):884-9. Nihon Naika Gakkai Zasshi. 2003. PMID: 12808916 Review. Japanese. No abstract available.
Cited by
- Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.
Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P. Dufies M, et al. Oncotarget. 2011 Nov;2(11):874-85. doi: 10.18632/oncotarget.360. Oncotarget. 2011. PMID: 22141136 Free PMC article. - ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R. Aceves-Luquero CI, et al. PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124. PLoS One. 2009. PMID: 19568437 Free PMC article. - Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.
Baran Y, Saydam G. Baran Y, et al. J Blood Med. 2012;3:139-50. doi: 10.2147/JBM.S29132. Epub 2012 Nov 16. J Blood Med. 2012. PMID: 23180974 Free PMC article. - Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models.
Muselli F, Mourgues L, Morcos R, Rochet N, Nebout M, Guerci-Bresler A, Faller DV, William RM, Mhaidly R, Verhoeyen E, Legros L, Peyron JF, Mary D. Muselli F, et al. Cancers (Basel). 2021 Apr 2;13(7):1693. doi: 10.3390/cancers13071693. Cancers (Basel). 2021. PMID: 33918475 Free PMC article. - Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.
Yoshida C, Melo JV. Yoshida C, et al. Int J Hematol. 2004 Jun;79(5):420-33. doi: 10.1532/ijh97.04032. Int J Hematol. 2004. PMID: 15239391 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous